OBJECTIVE: Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is a childhood encephalopathy following severe febrile seizures, leaving neurologic sequelae in many patients. However, its pathogenesis remains unclear. In this study, we clarified that genetic variation in the adenosine A2A receptor (ADORA2A), whose activation is involved in excitotoxicity, may be a predisposing factor of AESD. METHODS: We analyzed 4 ADORA2A single nucleotide polymorphisms in 85 patients with AESD. The mRNA expression in brain samples, mRNA and protein expression in lymphoblasts, as well as the production of cyclic adenosine monophosphate (cAMP) by lymphoblasts in response to adenosine were compared among ADORA2A diplotypes. RESULTS: Four single nucleotide polymorphisms were completely linked, which resulted in 2 haplotypes, A and B. Haplotype A (C at rs2298383, T at rs5751876, deletion at rs35320474, and C at rs4822492) frequency in patients was significantly higher than in controls (p = 0.005). Homozygous haplotype A (AA diplotype) had a higher risk of developing AESD (odds ratio 2.32, 95% confidence interval 1.32-4.08; p = 0.003) via a recessive model. mRNA expression was significantly higher in AA than AB and BB diplotypes, both in the brain (p = 0.003 and 0.002, respectively) and lymphoblasts (p = 0.035 and 0.003, respectively). In lymphoblasts, ADORA2A protein expression (p = 0.024), as well as cellular cAMP production (p = 0.0006), was significantly higher in AA than BB diplotype. CONCLUSIONS: AA diplotype of ADORA2A is associated with AESD and may alter the intracellular adenosine/cAMP cascade, thereby promoting seizures and excitotoxic brain damage in patients.
OBJECTIVE: Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is a childhood encephalopathy following severe febrile seizures, leaving neurologic sequelae in many patients. However, its pathogenesis remains unclear. In this study, we clarified that genetic variation in the adenosine A2A receptor (ADORA2A), whose activation is involved in excitotoxicity, may be a predisposing factor of AESD. METHODS: We analyzed 4 ADORA2A single nucleotide polymorphisms in 85 patients with AESD. The mRNA expression in brain samples, mRNA and protein expression in lymphoblasts, as well as the production of cyclic adenosine monophosphate (cAMP) by lymphoblasts in response to adenosine were compared among ADORA2A diplotypes. RESULTS: Four single nucleotide polymorphisms were completely linked, which resulted in 2 haplotypes, A and B. Haplotype A (C at rs2298383, T at rs5751876, deletion at rs35320474, and C at rs4822492) frequency in patients was significantly higher than in controls (p = 0.005). Homozygous haplotype A (AA diplotype) had a higher risk of developing AESD (odds ratio 2.32, 95% confidence interval 1.32-4.08; p = 0.003) via a recessive model. mRNA expression was significantly higher in AA than AB and BB diplotypes, both in the brain (p = 0.003 and 0.002, respectively) and lymphoblasts (p = 0.035 and 0.003, respectively). In lymphoblasts, ADORA2A protein expression (p = 0.024), as well as cellular cAMP production (p = 0.0006), was significantly higher in AA than BB diplotype. CONCLUSIONS: AA diplotype of ADORA2A is associated with AESD and may alter the intracellular adenosine/cAMP cascade, thereby promoting seizures and excitotoxic brain damage in patients.
Authors: Bertil B Fredholm; Jiang-Fan Chen; Rodrigo A Cunha; Per Svenningsson; Jean-Marie Vaugeois Journal: Int Rev Neurobiol Date: 2005 Impact factor: 3.230
Authors: J Takanashi; H Oba; A J Barkovich; H Tada; Y Tanabe; H Yamanouchi; S Fujimoto; M Kato; M Kawatani; A Sudo; H Ozawa; T Okanishi; M Ishitobi; Y Maegaki; Y Koyasu Journal: Neurology Date: 2006-05-09 Impact factor: 9.910
Authors: David C King; James Taylor; Laura Elnitski; Francesca Chiaromonte; Webb Miller; Ross C Hardison Journal: Genome Res Date: 2005-07-15 Impact factor: 9.043
Authors: V Arvydas Skeberdis; Vivien Chevaleyre; C Geoffrey Lau; Jesse H Goldberg; Diana L Pettit; Sylvia O Suadicani; Ying Lin; Michael V L Bennett; Rafael Yuste; Pablo E Castillo; R Suzanne Zukin Journal: Nat Neurosci Date: 2006-03-12 Impact factor: 24.884
Authors: Fabio C Tescarollo; Diogo M Rombo; Lindsay K DeLiberto; Denise E Fedele; Enmar Alharfoush; Ângelo R Tomé; Rodrigo A Cunha; Ana M Sebastião; Detlev Boison Journal: J Caffeine Adenosine Res Date: 2020-06-04